Market Research Logo

Pharmaceuticals Market Research Reports & Industry Analysis

The pharmaceutical industry is directly impacted by the research conducted with prescription drugs, vaccines, and OTC drugs being manufactured based on findings from the study of life sciences. Clinical trials are conducted to ensure that products being developed are tested on how well they work on individuals affected by the diseases or conditions they are created to treat. The market research available can provide investors and analysts credible information on the direction of pharmaceuticals, anesthesia, drug delivery, pricing, regulations and policy being developed to ensure that knowledgeable and informed decisions are made regarding industry direction.
...Show More ...Show Less


Pharmaceuticals Industry Research & Market Reports

  • Global Cancer Immunotherapy Market Analysis & Forecast to 2023 Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cel

    ... Analysis & Forecast to 2023 Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors Read More

  • Spain Pharmaceuticals & Healthcare Q1 2020

    ... of the generic drug sector and the government’s continuedfocus on cost-containment measures targeting prescription drug expenditure. These trends, along with a subdued economicoutlook, make Spain one of the more challenging markets in Western Europe for ... Read More

  • United Arab Emirates Pharmaceuticals & Healthcare Q1 2020

    ... of private healthcare coverage and the modernisationof health infrastructure will contribute to drive prescription market growth. Stricter pricing controls, generic drug substitution and anunfavourable demographic profile will cause headwinds to firms over the coming years. Read More

  • Vietnam Pharmaceuticals & Healthcare Q1 2020

    ... schemes, andauthorities' support for pharmaceutical investment are just some of the factors that would provide a fertile ground for substantialvolume and value growth. However, this potential will mostly attract generic drug companies, given the low ... Read More

  • Puerto Rico Pharmaceuticals & Healthcare Q1 2020

    ... pressure on the high medicine pricing is becoming moreintense. The financial sustainability of Puerto Rico’s healthcare sector is increasingly under pressure. There are significant economicheadwinds, along with recent political upheavals. Sales of pharmaceuticals and healthcare ... Read More

  • Serbia Pharmaceuticals & Healthcare Q1 2020

    ... affordability levels, weak access to healthcare and a challenging regulatory environment. However, increasing purchasing poweramid rising real wages along with an ageing population and a rising chronic disease burden will provide long-term growth prospectsfor drugmakers. Read More

  • Cuba Pharmaceuticals & Healthcare Q1 2020

    ... into commercial opportunities fordrugmakers in the long term, a poor intellectual property environment with limited respect for patents and a strong domesticpharmaceutical industry weaken prospects for innovative drugs sales. Furthermore, emigration and a shrinking working-agepopulation ... Read More

  • Lithuania Pharmaceuticals & Healthcare Q1 2020

    ... its small population size and thus, limited growth potential willcontinue to hinder commercial opportunities in its pharmaceutical market. Nevertheless, the wide reimbursement coverageremains a draw for multinationals that operate regionally and bid for government tenders.. Read More

  • Malaysia Pharmaceuticals & Healthcare Q1 2020

    ... a non-transparent process to issue compulsorylicenses will continue to undermine investment by innovative drugmakers in the country. Furthermore, the Malaysianpharmaceutical market will be faced with a myriad of challenges in Malaysia, including weak intellectual property ... Read More

  • Mexico Pharmaceuticals & Healthcare Q1 2020

    ... access to healthcare services andmedications through a new public health trust, although the financing for this additional coverage is still not sufficiently clear whilethe transition phase pose downside risk to access to treatment. In response ... Read More

  • Peru Pharmaceuticals & Healthcare Q1 2020

    ... of listed generic drugs, lacks extensive detailsbut has already faced opposition from industry. Despite the government’s increased commitment to the health sector, a weakeconomic outlook and political uncertainty will limit external and internal investment in ... Read More

  • Nigeria Pharmaceuticals & Healthcare Q1 2020

    ... country’s attractiveness to innovative drugmakers. This is exacerbated by regulatory inefficiencies and high prevalence ofcounterfeit medicines. The goal of achievement of universal healthcare by 2030 will continue to be threatened by a number ofstructural issues. Read More

  • Germany Pharmaceuticals & Healthcare Q1 2020

    ... to services, will continue tosupport this potential. However, we do caution that market access is now challenging, as authorities use a range of cost-containment measures and downward price pressures as a means of controlling state ... Read More

  • Kyrgyzstan Pharmaceuticals & Healthcare Q1 2020

    ... for drug sales limited to non-branded non-prescription and genericmedicines. The market will remain highly unattractive to innovative drugmakers also on account of the presence of counterfeitmedicines and challenges in supply and distribution across the country. Read More

  • Lebanon Pharmaceuticals & Healthcare Q1 2020

    ... remain reliant onmedicine imports from more developed nearby markets in the short-to-medium term. The country’s public health sector hasbenefited from numerous supports schemes following the Syrian war, improving the populations access to healthcare. However,international aid ... Read More

  • Portugal Pharmaceuticals & Healthcare Q1 2020

    ... Portuguese market, thereby limiting their ability to capitalise on price variationsacross the EU. Portugal’s pharmaceutical market will grow over the forecast period, although a repressive pricing environment and aweak reimbursement profile will limit its attractiveness ... Read More

  • Sri Lanka Pharmaceuticals & Healthcare Q1 2020

    ... foreshadow an increase in chronic disease burdens. Local drug productionwill continue to gradually increase, with public procurement policies favouring local manufacturers, although small economies ofscale and a challenging regulatory and operating environment will continue to ... Read More

  • Tunisia Pharmaceuticals & Healthcare Q1 2020

    ... operations in the country owing to anumber of industry- and country-related risks. This is exacerbated by longstanding shortcomings in the healthcare system. As aresult, growth in the country's pharmaceutical and healthcare market will remain repressed. Read More

  • Tanzania Pharmaceuticals & Healthcare Q1 2020

    ... will have only a limited effect aslongstanding issues will remain in place. Low life expectancy and a young population will limit the uptake of high-value medicines.Nonetheless, with one of the highest birth rates in the ... Read More

  • Global Animal Health (Feed Additives, Pharmaceuticals & Vaccines) Market Report: Insights, Trends & Forecast (2019-2023)

    ... The market is predicted to reach US$52.53 billion in 2023. Growth in the global animal health market is expected to be driven by various factors such as rising disposable income, growing cattle population, increasing urban ... Read More

  • Biotechnology Product Manufacturing

    ... Switzerland-based Roche), Gilead Sciences, and Monsanto, as well as CSL (Australia), Merck KGaA (Germany), Novo Nordisk (Denmark), and the biotech research arms of major international pharmaceutical companies such as Sanofi (France). COMPETITIVE LANDSCAPE Biotech firms ... Read More

  • Pharmaceutical Manufacturing

    ... in the US), as well as AstraZeneca (UK), Bayer (Germany), GlaxoSmithKline (UK), Novartis (Switzerland), Roche Holding (Switzerland), and Sanofi (France). COMPETITIVE LANDSCAPE Pharmaceutical manufacturers compete to discover and commercialize ever-more effective medicines. Companies focus on ... Read More

  • Abscess - Market Insights, Epidemiology and Market Forecast – 2028

    ... forecasted Abscess epidemiology. It highlights the existing treatment patterns, potential upcoming Abscess drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during ... Read More

  • Acne - Market Insights, Epidemiology and Market Forecast – 2028

    ... forecasted Acne epidemiology. It highlights the existing treatment patterns, potential upcoming Acne drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during ... Read More

  • Amyotrophic Lateral Sclerosis - Market Insights, Epidemiology and Market Forecast – 2028

    ... understanding of historical and forecasted Amyotrophic Lateral Sclerosis epidemiology. It highlights the existing treatment patterns, potential upcoming Amyotrophic Lateral Sclerosis drugs and also identifies best of the market opportunities by providing the current and forecasted ... Read More

< prev 1 3 4 5 6 7 8 9 10